{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:54:55Z","timestamp":1794023695907,"version":"4.8.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"\n Importance<\/jats:title>\n Neoadjuvant systemic therapy (NST) has been associated with pathologic complete response (pCR) in up to 60% of breast cancers (BCs). The findings of this trial question the necessity of surgery.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To report preplanned 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients selected with image-guided vacuum assisted biopsy (VAB).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This single-arm, prospective, phase 2 nonrandomized clinical trial was conducted at 7 US medical centers and included women 40 years or older with cT1-2N0-1M0\n ERBB2<\/jats:italic>\n -positive (formerly\n HER2<\/jats:italic>\n -positive) or triple-negative invasive BC who showed residual breast lesions after NST of less than 2 cm on imaging. Enrollment was from March 6, 2017, to November 9, 2021. Data analysis was from October to December 2024.\n <\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Image-guided VAB of the tumor bed (9G with a minimum of 12 cores) was performed after standard NST. Patients with clinically node-negative disease at diagnosis and no residual cancer in the breast on post-NST VAB underwent whole-breast radiotherapy with a boost without breast or axillary surgery. Patients with initial documented nodal disease and a breast pCR on VAB underwent targeted axillary dissection, while those with residual cancer when undergoing VAB had standard breast and axillary surgery. Patients were monitored with physical examinations and mammography every 6 months.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome Measures<\/jats:title>\n The primary outcome was ipsilateral breast tumor recurrence.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Fifty patients (median [IQR] age, 62 [55-77] years) were enrolled and underwent post-NST VAB. Twenty-nine (58%) and 21 (42%) patients had\n ERBB2<\/jats:italic>\n -positive and triple-negative invasive BC, respectively. Breast pCR on VAB was identified in 31 patients (62%; 95% CI, 47.2%-75.34%), and axillary pCR was identified among all 8 patients with initial nodal metastases and breast pCR on VAB who underwent targeted axillary dissection. At a median follow-up of 55.4 (IQR, 44.0-63.5) months, the ipsilateral breast tumor recurrence rate was 0%, and disease-free and overall survival rates were 100% for patients without breast surgery.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this nonrandomized clinical trial that reported preplanned 5-year outcomes suggest that omission of breast surgery in select patients after NST may be feasible, with no recurrences seen. More confirmatory studies are necessary before this new approach alters surgical practice.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02945579<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.0207","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T08:32:35Z","timestamp":1743150755000},"page":"529","source":"Crossref","is-referenced-by-count":46,"title":["Selective Elimination of Breast Surgery for Invasive Breast Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Henry M.","family":"Kuerer","sequence":"first","affiliation":[{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitri","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia J.","family":"Diego","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, University of Pittsburgh Medical Center Magee-Womens Hospital, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lucci","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona F.","family":"Shaitelman","sequence":"additional","affiliation":[{"name":"Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa P.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[{"name":"Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"White","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, Carolinas Medical Center, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei T.","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaiane M.","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Exceptional Responders Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya W","family":"Moseley","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica WT","family":"Leung","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Huang","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind P","family":"Candelaria","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz E","family":"Adrada","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Arribas","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel FD","family":"van la Parra","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Ramirez","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mediget","family":"Teshome","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa F","family":"Hwang","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makesha V","family":"Miggins","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Piotrowski","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P","family":"Refinetti","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Ehlers","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Mouabbi","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Suarez Colen","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E","family":"Loveland-Jones","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Ann","family":"Lesnikowski","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Samiian","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton D","family":"Chong","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalliah M","family":"Black","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Desyder","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie X","family":"Sun","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K","family":"Hunt","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen M","family":"Nguyen","sequence":"additional","affiliation":[{"name":"for the Exceptional Responders Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"coi250006r1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","article-title":"A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy.","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann Surg"},{"issue":"12","key":"coi250006r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2020.4103","article-title":"Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer.","volume":"155","author":"Tasoulis","year":"2020","journal-title":"JAMA Surg"},{"issue":"12","key":"coi250006r3","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","article-title":"Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.","volume":"23","author":"Kuerer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"coi250006r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.33933","article-title":"Patient-reported outcomes of omission of breast surgery following neoadjuvant systemic therapy: a nonrandomized clinical trial.","volume":"6","author":"Johnson","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"coi250006r6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/XCS.0000000000000670","article-title":"Eliminating breast surgery for invasive cancer with exceptional response to neoadjuvant systemic therapy: prospective multicenter clinical trial planned initial feasibility endpoint.","volume":"237","author":"Johnson","year":"2023","journal-title":"J Am Coll Surg"},{"issue":"1","key":"coi250006r7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1186\/s12885-024-12689-6","article-title":"Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"coi250006r8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13058-016-0684-6","article-title":"Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.","volume":"18","author":"van la Parra","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"18","key":"coi250006r9","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-17-0255","article-title":"Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant \u201cGeparquattro\u201d trial.","volume":"23","author":"Riethdorf","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi250006r10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10549-020-05658-7","article-title":"Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.","volume":"181","author":"O\u2019Toole","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"coi250006r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102362","article-title":"Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: a systematic review and meta-analysis.","volume":"104","author":"Papakonstantinou","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"coi250006r12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1177\/0272989X14564432","article-title":"Decision regret following treatment for localized breast cancer: is regret stable over time?","volume":"35","author":"Martinez","year":"2015","journal-title":"Med Decis Making"},{"issue":"2","key":"coi250006r13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijrobp.2021.05.004","article-title":"Five-year longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation.","volume":"111","author":"Weng","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"coi250006r14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.ejso.2020.03.208","article-title":"De-escalation towards omission is the tipping point of individualizing breast cancer surgery.","volume":"46","author":"Heil","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"coi250006r15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection.","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250006r16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamasurg.2014.1086","article-title":"Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial.","volume":"150","author":"Caudle","year":"2015","journal-title":"JAMA Surg"},{"issue":"16","key":"coi250006r17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"coi250006r18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial.","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"coi250006r19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial.","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"coi250006r20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.26698","article-title":"Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ: the COMET randomized clinical trial.","author":"Hwang","journal-title":"JAMA"},{"key":"coi250006r4","author":"Kuerer"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2832067\/jamaoncology_kuerer_2025_oi_250006_1747255286.31905.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:01:25Z","timestamp":1747306885000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2832067"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.0207","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}